Access to essential medicines of the future

17
Access to essential medicines of the future Bernard Pécoul Director, Campaign for Access to Essential Medicines Médecins Sans Frontières

description

Access to essential medicines of the future. Bernard Pécoul Director, Campaign for Access to Essential Medicines Médecins Sans Frontières. A sleeping sickness patient, N'dalatando , Angola, 1997. Justice Access to essential medicines as a human right Essential medicines as public goods. - PowerPoint PPT Presentation

Transcript of Access to essential medicines of the future

Page 1: Access to essential medicines  of the future

Access to essential medicines

of the future

Bernard PécoulDirector, Campaign for Access to Essential

MedicinesMédecins Sans Frontières

Page 2: Access to essential medicines  of the future

A sleeping sickness patient, N'dalatando, Angola, 1997

Page 3: Access to essential medicines  of the future

• Justice

• Access to essential medicines as a

human right

• Essential medicines as public

goods

Page 4: Access to essential medicines  of the future

Justice

Page 5: Access to essential medicines  of the future
Page 6: Access to essential medicines  of the future

The right of access to essential

medicines

Page 7: Access to essential medicines  of the future
Page 8: Access to essential medicines  of the future

Essential medicines as public goods

Page 9: Access to essential medicines  of the future

• Some essential medicines still not on the List

• Overcome intellectual property barriers to access

• Address R&D crisis for medicines for developing

country diseases

• Maintain the production of essential medicines

and secure the market

Future challenges for essential medicines

Page 10: Access to essential medicines  of the future

Some essential medicines still not

included on the List

Page 11: Access to essential medicines  of the future

Overcome intellectual property

barriers to access

Page 12: Access to essential medicines  of the future

The Effects of Generic CompetitionStavudine (d4T) + lamivudine (3TC) + nevirapine (NVP):

Lowest world prices per patient per year

Page 13: Access to essential medicines  of the future

Address R&D crisis for medicines for

developing country diseases

Page 14: Access to essential medicines  of the future

Research for drugs for neglected diseases

1975 to 1999: 1,393 new chemical entities marketed

Tropical diseases: 13

Tuberculosis: 3

Page 15: Access to essential medicines  of the future

Maintain the production of essential

medicines and secure the market

Page 16: Access to essential medicines  of the future
Page 17: Access to essential medicines  of the future